Literature DB >> 25673567

Faecal occult blood testing for colorectal cancer screening: the past or the future.

Sally C Benton1, Helen E Seaman, Stephen P Halloran.   

Abstract

Screening for colorectal cancer (CRC) reduces CRC mortality; many countries have implemented population-based CRC screening programmes and many more are poised to do so. Whilst several different CRC screening modalities are available, choice will be influenced by cost, available resources (e.g. high-quality colonoscopy) and acceptability of the test by the invited population. For CRC screening, no screening test has so far surpassed the practicality, affordability and effectiveness of tests for the presence of blood in faeces (faecal occult blood tests, FOBt). The results of several large FOBt-based randomised controlled trials provide the best clinical evidence to support their use in population-based CRC screening. This review considers the current options for CRC screening and the future for FOBt.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25673567     DOI: 10.1007/s11894-015-0428-2

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  71 in total

Review 1.  Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening.

Authors:  Linda Rabeneck; R Bryan Rumble; Frank Thompson; Michael Mills; Curtis Oleschuk; Alexandra Whibley; Hans Messersmith; Nancy Lewis
Journal:  Can J Gastroenterol       Date:  2012-03       Impact factor: 3.522

Review 2.  Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update.

Authors:  Paul Hewitson; Paul Glasziou; Eila Watson; Bernie Towler; Les Irwig
Journal:  Am J Gastroenterol       Date:  2008-05-13       Impact factor: 10.864

Review 3.  Colonoscopy perforation rate, mechanisms and outcome: from diagnostic to therapeutic colonoscopy.

Authors:  V Panteris; J Haringsma; E J Kuipers
Journal:  Endoscopy       Date:  2009-10-28       Impact factor: 10.093

4.  Randomised controlled trial of faecal-occult-blood screening for colorectal cancer.

Authors:  J D Hardcastle; J O Chamberlain; M H Robinson; S M Moss; S S Amar; T W Balfour; P D James; C M Mangham
Journal:  Lancet       Date:  1996-11-30       Impact factor: 79.321

5.  Stool DNA and occult blood testing for screen detection of colorectal neoplasia.

Authors:  David A Ahlquist; Daniel J Sargent; Charles L Loprinzi; Theodore R Levin; Douglas K Rex; Dennis J Ahnen; Kandice Knigge; M Peter Lance; Lawrence J Burgart; Stanley R Hamilton; James E Allison; Michael J Lawson; Mary E Devens; Jonathan J Harrington; Shauna L Hillman
Journal:  Ann Intern Med       Date:  2008-10-07       Impact factor: 25.391

6.  Multitarget stool DNA testing for colorectal-cancer screening.

Authors:  Thomas F Imperiale; David F Ransohoff; Steven H Itzkowitz; Theodore R Levin; Philip Lavin; Graham P Lidgard; David A Ahlquist; Barry M Berger
Journal:  N Engl J Med       Date:  2014-03-19       Impact factor: 91.245

7.  Inequalities in participation in an organized national colorectal cancer screening programme: results from the first 2.6 million invitations in England.

Authors:  Christian von Wagner; Gianluca Baio; Rosalind Raine; Julia Snowball; Stephen Morris; Wendy Atkin; Austin Obichere; Graham Handley; Richard F Logan; Sandra Rainbow; Stephen Smith; Stephen Halloran; Jane Wardle
Journal:  Int J Epidemiol       Date:  2011-02-17       Impact factor: 7.196

8.  Faecal haemoglobin concentration is related to severity of colorectal neoplasia.

Authors:  Jayne Digby; Callum G Fraser; Francis A Carey; Paula J McDonald; Judith A Strachan; Robert H Diament; Margaret Balsitis; Robert J C Steele
Journal:  J Clin Pathol       Date:  2013-02-15       Impact factor: 3.411

9.  Performance measures in three rounds of the English bowel cancer screening pilot.

Authors:  S M Moss; C Campbell; J Melia; D Coleman; S Smith; R Parker; P Ramsell; J Patnick; D P Weller
Journal:  Gut       Date:  2011-05-10       Impact factor: 23.059

Review 10.  Effect of flexible sigmoidoscopy-based screening on incidence and mortality of colorectal cancer: a systematic review and meta-analysis of randomized controlled trials.

Authors:  B Joseph Elmunzer; Rodney A Hayward; Philip S Schoenfeld; Sameer D Saini; Amar Deshpande; Akbar K Waljee
Journal:  PLoS Med       Date:  2012-12-04       Impact factor: 11.069

View more
  5 in total

1.  Willingness to pay for colorectal cancer screening in Guangzhou.

Authors:  Qin Zhou; Yan Li; Hua-Zhang Liu; Ying-Ru Liang; Guo-Zhen Lin
Journal:  World J Gastroenterol       Date:  2018-11-07       Impact factor: 5.742

2.  Diffusion-weighted whole-body imaging with background body signal suppression/T2 image fusion for the diagnosis of colorectal polyp and cancer.

Authors:  Minoru Tomizawa; Fuminobu Shinozaki; Yoshitaka Uchida; Katsuhiro Uchiyama; Kazunori Fugo; Takafumi Sunaoshi; Aika Ozaki; Eriko Sugiyama; Akira Baba; Daisuke Kano; Misaki Shite; Ryota Haga; Yoshiya Fukamizu; Satoshi Kagayama; Rumiko Hasegawa; Yoshinori Shirai; Yasufumi Motoyoshi; Takao Sugiyama; Shigenori Yamamoto; Takashi Kishimoto; Naoki Ishige
Journal:  Exp Ther Med       Date:  2016-12-16       Impact factor: 2.447

3.  Characteristics of colorectal cancer diagnosed with screening abdominal ultrasonography.

Authors:  Minoru Tomizawa; Fuminobu Shinozaki; Rumiko Hasegawa; Kazunori Fugo; Yoshinori Shirai; Yasufumi Motoyoshi; Takao Sugiyama; Shigenori Yamamoto; Takashi Kishimoto; Naoki Ishige
Journal:  Mol Clin Oncol       Date:  2016-05-11

Review 4.  Faecal Occult Blood Point-of-Care Tests.

Authors:  Barbara Kościelniak-Merak; Branimir Radosavljević; Andrzej Zając; Przemysław J Tomasik
Journal:  J Gastrointest Cancer       Date:  2018-12

5.  A Blood Test for Methylated BCAT1 and IKZF1 vs. a Fecal Immunochemical Test for Detection of Colorectal Neoplasia.

Authors:  Erin L Symonds; Susanne K Pedersen; Rohan T Baker; David H Murray; Snigdha Gaur; Stephen R Cole; Geetha Gopalsamy; Dileep Mangira; Lawrence C LaPointe; Graeme P Young
Journal:  Clin Transl Gastroenterol       Date:  2016-01-14       Impact factor: 4.488

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.